amiodarone and Ventricular Dysfunction, Left studies

Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.

Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.

Research Excerpts

Excerpt	Relevance	Reference
"Amiodarone's efficacy in maintaining sinus rhythm and reducing the burden of atrial fibrillation is similar in the presence or absence of severe left ventricular dysfunction."	9.19	Efficacy of amiodarone in patients with atrial fibrillation with and without left ventricular dysfunction: a pooled analysis of AFFIRM and AF-CHF trials. ( Andrade, JG; Blondeau, L; Cadrin-Tourigny, J; Dubuc, M; Guerra, PG; Khairy, P; Levesque, S; Macle, L; Rivard, L; Roy, D; Talajic, M; Thibault, B; Wyse, DG, 2014)
"Dronedarone is a new multichannel blocking antiarrhythmic drug for treatment of atrial fibrillation (AF)."	9.14	Dronedarone in patients with congestive heart failure: insights from ATHENA. ( Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2010)
"In a multicenter study with a double-blind design, we planned to randomly assign 1000 patients who were hospitalized with symptomatic heart failure and severe left ventricular systolic dysfunction to receive 400 mg of dronedarone twice a day or placebo."	9.13	Increased mortality after dronedarone therapy for severe heart failure. ( Amlie, J; Carlsen, J; Crijns, H; Gøtzsche, O; Køber, L; Lévy, S; McMurray, JJ; Torp-Pedersen, C, 2008)
" Amiodarone either has no effect or improves the haemodynamics in patients with left ventricular dysfunction, but its effect on BNP is unknown."	9.10	Amiodarone decreases plasma brain natriuretic peptide level in patients with heart failure and ventricular tachyarrhythmia. ( Hagiwara, N; Hosaka, F; Kajimoto, K; Kasanuki, H; Matsuda, N; Shiga, T; Shoda, M; Tanizaki, K; Wakaumi, M, 2003)
"We sought to compare the long-term survival rates of patients with sustained ventricular tachyarrhythmia after myocardial infarction (MI) who were treated according to the results of electrophysiological (EP) study either with amiodarone or an implantable cardioverter-defibrillator (ICD)."	9.10	Electrophysiologically guided amiodarone therapy versus the implantable cardioverter-defibrillator for sustained ventricular tachyarrhythmias after myocardial infarction: results of long-term follow-up. ( Fromer, M; Kappenberger, L; Rapp, F; Schläpfer, J, 2002)
"Our findings do not support the systematic prophylactic use of amiodarone in all patients with depressed left-ventricular function after myocardial infarction."	9.08	Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. ( Camm, AJ; Frangin, G; Janse, MJ; Julian, DG; Munoz, A; Schwartz, PJ; Simon, P, 1997)
"The efficacy and safety of amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation was examined by reviewing the trials on the subject identified through a comprehensive literature search."	8.82	Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. ( Gowda, RM; Khan, IA; Mehta, NJ, 2003)
"Patients with amiodarone-induced thyrotoxicosis (AIT) and left ventricular (LV) systolic dysfunction have a high mortality rate."	7.78	Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction. ( Bartalena, L; Bogazzi, F; De Napoli, L; Marchello, A; Mariotti, R; Martino, E; Materazzi, G; Miccoli, P; Moretti, M; Rossi, G; Tomisti, L, 2012)
"Amiodarone-induced thyrotoxicosis (AIT) with features consistent with both AIT type I (in which thyroid antibodies and nodular goiter are present) and AIT type II (which is not responsive to thionamide therapy and eventually leads to permanent hypothyroidism)."	7.74	Treatment of amiodarone-associated thyrotoxicosis. ( Franklyn, JA; Gammage, MD, 2007)
"Amiodarone-induced thyrotoxicosis (AIT) is a challenging management problem, since patients treated with amiodarone invariably have underlying heart disease."	7.73	Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. ( Diamond, T; Lewis, M; O'Sullivan, AJ, 2006)
"Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) studied whether a standardized protocol for the initiation and titration of the beta-blocker carvedilol in a multicenter, open-label program would optimize beta-blocker use in heart failure (HF) patients."	7.73	Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry. ( Diaz, A; Doval, H; Ferrante, D; Grancelli, H; Nul, D; Soifer, S; Varini, S; Zambrano, C, 2005)
"Amiodarone use for the prevention of recurrent atrial fibrillation or atrial flutter requires drug loading over a period of several days to weeks, whereas class 1C agents do not."	7.72	Early recurrence of arrhythmia in patients taking amiodarone or class 1C agents for treatment of atrial fibrillation or atrial flutter. ( Hauser, TH; Josephson, ME; Pinto, DS; Zimetbaum, P, 2004)
"To determine the efficacy necessary to make prophylactic ICD or amiodarone therapy cost-effective in patients with myocardial infarction."	7.71	Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. ( Every, NR; Heidenreich, PA; Hlatky, MA; McDonald, KM; Owens, DK; Parsons, LS; Sanders, GD, 2001)
"1 years, range 9 months-10 years (two with incessant ventricular tachycardia, one with ectopic atrial tachycardia, two with atrioventricular re-entrant tachycardia (three episodes), four with postoperative or congenital junctional ectopic tachycardia, two with bradycardia-tachycardia syndrome, one with atrial tachycardia) were treated with intravenous amiodarone during 13 tachycardia episodes."	7.70	Effectiveness and safety of intravenous amiodarone in drug-resistant tachyarrhythmias of children. ( Celiker, A; Ceviz, N; Ozme, S, 1998)
"A retrospective review was done to determine the efficacy and hemodynamic effects of slow intravenous amiodarone administration on invasively monitored patients with acute onset of atrial fibrillation or atrial flutter and left ventricular ejection fractions < 15%."	7.69	Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function. ( Kumar, A, 1996)
"Dronedarone was well tolerated and, as expected, decreased heart rate."	6.75	Effect of dronedarone on exercise capacity and cardiac function in patients with severe left ventricular dysfunction and compensated stable heart failure. ( Ghali, JK; Giles, T; Levine, TB; Radzik, D, 2010)
"Amiodarone was administered at a dosage of 800 mg/day for 2 weeks followed by 400 mg/day thereafter."	6.68	Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA). ( Gambarte, A; Garguichevich, JJ; Gentile, A; Hauad, S; Ramos, JL; Scapin, O; Sirena, J; Tibaldi, M; Toplikar, J, 1995)
"On day 21, he was complicated with acute respiratory distress syndrome."	5.33	Fatal case of amiodarone-induced acute respiratory distress syndrome in a patient with severe left ventricular dysfunction due to extensive anterior acute myocardial infarction. ( Ando, H; Eto, Y; Fukumoto, Y; Ikeuchi, M; Kishi, T; Kuwata, K; Nakamura, R; Okamatsu, S; Ozawa, M; Sekiya, M; Sobashima, A; Yamada, A; Yamawaki, T, 2006)
"Amiodarone's efficacy in maintaining sinus rhythm and reducing the burden of atrial fibrillation is similar in the presence or absence of severe left ventricular dysfunction."	5.19	Efficacy of amiodarone in patients with atrial fibrillation with and without left ventricular dysfunction: a pooled analysis of AFFIRM and AF-CHF trials. ( Andrade, JG; Blondeau, L; Cadrin-Tourigny, J; Dubuc, M; Guerra, PG; Khairy, P; Levesque, S; Macle, L; Rivard, L; Roy, D; Talajic, M; Thibault, B; Wyse, DG, 2014)
"Dronedarone is a new multichannel blocking antiarrhythmic drug for treatment of atrial fibrillation (AF)."	5.14	Dronedarone in patients with congestive heart failure: insights from ATHENA. ( Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2010)
"In a multicenter study with a double-blind design, we planned to randomly assign 1000 patients who were hospitalized with symptomatic heart failure and severe left ventricular systolic dysfunction to receive 400 mg of dronedarone twice a day or placebo."	5.13	Increased mortality after dronedarone therapy for severe heart failure. ( Amlie, J; Carlsen, J; Crijns, H; Gøtzsche, O; Køber, L; Lévy, S; McMurray, JJ; Torp-Pedersen, C, 2008)
"Perindopril was used in 287 patients with left ventricular ejection fraction < or =40% for 1 year after myocardial infarction either alone (n=53), or in combination with amiodarone (n=53), metoprolol (n=32), bisoprolol (n=32), carvedilol (n=32), atenolol (n=32), amiodarone and carvedilol (n=53)."	5.11	[Dynamics of postinfarction left ventricular remodeling during long term use of perindopril, amiodarone, and beta-adrenoblockers]. ( Bozhko, AA; Kanorskiĭ, SG; Staritskiĭ, AG, 2005)
" Amiodarone either has no effect or improves the haemodynamics in patients with left ventricular dysfunction, but its effect on BNP is unknown."	5.10	Amiodarone decreases plasma brain natriuretic peptide level in patients with heart failure and ventricular tachyarrhythmia. ( Hagiwara, N; Hosaka, F; Kajimoto, K; Kasanuki, H; Matsuda, N; Shiga, T; Shoda, M; Tanizaki, K; Wakaumi, M, 2003)
"We sought to compare the long-term survival rates of patients with sustained ventricular tachyarrhythmia after myocardial infarction (MI) who were treated according to the results of electrophysiological (EP) study either with amiodarone or an implantable cardioverter-defibrillator (ICD)."	5.10	Electrophysiologically guided amiodarone therapy versus the implantable cardioverter-defibrillator for sustained ventricular tachyarrhythmias after myocardial infarction: results of long-term follow-up. ( Fromer, M; Kappenberger, L; Rapp, F; Schläpfer, J, 2002)
"Our findings do not support the systematic prophylactic use of amiodarone in all patients with depressed left-ventricular function after myocardial infarction."	5.08	Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. ( Camm, AJ; Frangin, G; Janse, MJ; Julian, DG; Munoz, A; Schwartz, PJ; Simon, P, 1997)
" Other agents such as Vernakalant and Ranolazine are in development that promise to be more atrial selective in their action, thereby potentially avoiding pro-arrhythmia and heart failure side effects."	4.88	Novel anti-arrhythmic medications in the treatment of atrial fibrillation. ( Saklani, P; Skanes, A, 2012)
"The efficacy and safety of amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation was examined by reviewing the trials on the subject identified through a comprehensive literature search."	4.82	Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. ( Gowda, RM; Khan, IA; Mehta, NJ, 2003)
"Patients with amiodarone-induced thyrotoxicosis (AIT) and severely reduced left ventricular ejection fraction (LVEF) have a high mortality rate that may be reduced by total thyroidectomy."	3.96	Duration of Exposure to Thyrotoxicosis Increases Mortality of Compromised AIT Patients: the Role of Early Thyroidectomy. ( Bartalena, L; Bogazzi, F; Cappellani, D; Cosentino, G; Di Certo, AM; Manetti, L; Marconcini, G; Martino, E; Materazzi, G; Morganti, R; Papini, P; Tanda, ML; Urbani, C, 2020)
"Patients with amiodarone-induced thyrotoxicosis (AIT) and left ventricular (LV) systolic dysfunction have a high mortality rate."	3.78	Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction. ( Bartalena, L; Bogazzi, F; De Napoli, L; Marchello, A; Mariotti, R; Martino, E; Materazzi, G; Miccoli, P; Moretti, M; Rossi, G; Tomisti, L, 2012)
"Amiodarone protects patients with left ventricular systolic dysfunction (LVSD) against serious arrhythmias, but it also has numerous side effects on non-cardiac organs, such as the thyroid."	3.77	Thyroid hormone, amiodarone therapy, and prognosis in left ventricular systolic dysfunction. ( Carpeggiani, C; Coceani, M; Iervasi, G; L'abbate, A; Landi, P; Molinaro, S; Pingitore, A; Scalese, M, 2011)
"Amiodarone-induced thyrotoxicosis (AIT) with features consistent with both AIT type I (in which thyroid antibodies and nodular goiter are present) and AIT type II (which is not responsive to thionamide therapy and eventually leads to permanent hypothyroidism)."	3.74	Treatment of amiodarone-associated thyrotoxicosis. ( Franklyn, JA; Gammage, MD, 2007)
"Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) studied whether a standardized protocol for the initiation and titration of the beta-blocker carvedilol in a multicenter, open-label program would optimize beta-blocker use in heart failure (HF) patients."	3.73	Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry. ( Diaz, A; Doval, H; Ferrante, D; Grancelli, H; Nul, D; Soifer, S; Varini, S; Zambrano, C, 2005)
"Amiodarone-induced thyrotoxicosis (AIT) is a challenging management problem, since patients treated with amiodarone invariably have underlying heart disease."	3.73	Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. ( Diamond, T; Lewis, M; O'Sullivan, AJ, 2006)
"Baroreflex sensitivity was assessed in 287 patients with history of myocardial infarction and left ventricular ejection fraction < or =40% by phenylephrine test and was found to be depressed (4."	3.72	[Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction]. ( Bozhko, AA; Kanopskiĭ, SG; Staritskiĭ, AG, 2004)
"Amiodarone use for the prevention of recurrent atrial fibrillation or atrial flutter requires drug loading over a period of several days to weeks, whereas class 1C agents do not."	3.72	Early recurrence of arrhythmia in patients taking amiodarone or class 1C agents for treatment of atrial fibrillation or atrial flutter. ( Hauser, TH; Josephson, ME; Pinto, DS; Zimetbaum, P, 2004)
"To determine the efficacy necessary to make prophylactic ICD or amiodarone therapy cost-effective in patients with myocardial infarction."	3.71	Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. ( Every, NR; Heidenreich, PA; Hlatky, MA; McDonald, KM; Owens, DK; Parsons, LS; Sanders, GD, 2001)
"The effect of oral amiodarone (AMD) therapy on left ventricular (LV) function was evaluated retrospectively in Japanese patients with ventricular tachyarrhythmias and congestive heart failure."	3.70	Effect of relatively low dose amiodarone therapy on left ventricular function in patients with ventricular tachyarrhythmias. ( Yamada, S; Yamaguchi, I, 1998)
"1 years, range 9 months-10 years (two with incessant ventricular tachycardia, one with ectopic atrial tachycardia, two with atrioventricular re-entrant tachycardia (three episodes), four with postoperative or congenital junctional ectopic tachycardia, two with bradycardia-tachycardia syndrome, one with atrial tachycardia) were treated with intravenous amiodarone during 13 tachycardia episodes."	3.70	Effectiveness and safety of intravenous amiodarone in drug-resistant tachyarrhythmias of children. ( Celiker, A; Ceviz, N; Ozme, S, 1998)
"A retrospective review was done to determine the efficacy and hemodynamic effects of slow intravenous amiodarone administration on invasively monitored patients with acute onset of atrial fibrillation or atrial flutter and left ventricular ejection fractions < 15%."	3.69	Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function. ( Kumar, A, 1996)
"Dronedarone was well tolerated and, as expected, decreased heart rate."	2.75	Effect of dronedarone on exercise capacity and cardiac function in patients with severe left ventricular dysfunction and compensated stable heart failure. ( Ghali, JK; Giles, T; Levine, TB; Radzik, D, 2010)
"In patients with atrial fibrillation and congestive heart failure, a routine strategy of rhythm control does not reduce the rate of death from cardiovascular causes, as compared with a rate-control strategy."	2.73	Rhythm control versus rate control for atrial fibrillation and heart failure. ( Arnold, JM; Bourassa, MG; Buxton, AE; Camm, AJ; Connolly, SJ; Dorian, P; Dubuc, M; Ducharme, A; Guerra, PG; Hohnloser, SH; Lambert, J; Le Heuzey, JY; Lee, KL; Nattel, S; O'Hara, G; Pedersen, OD; Rouleau, JL; Roy, D; Singh, BN; Stevenson, LW; Stevenson, WG; Talajic, M; Thibault, B; Waldo, AL; Wyse, DG, 2008)
" Adverse events occurred in 17 patients (3 died, 3 had bradycardia that required permanent pacemaker implantation, and 11 had bradycardia requiring a decrease in the dose of antiarrhythmic or rate-controlling medication)."	2.71	Safety and feasibility of a clinical pathway for the outpatient initiation of antiarrhythmic medications in patients with atrial fibrillation or atrial flutter. ( Hauser, TH; Josephson, ME; Pinto, DS; Zimetbaum, P, 2003)
"Amiodarone was administered at a dosage of 800 mg/day for 2 weeks followed by 400 mg/day thereafter."	2.68	Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA). ( Gambarte, A; Garguichevich, JJ; Gentile, A; Hauad, S; Ramos, JL; Scapin, O; Sirena, J; Tibaldi, M; Toplikar, J, 1995)
" Thus, co-administration of antioxidants with amiodarone may lead to the more widespread application of amiodarone, which is currently the most potent available antiarrhythmic agent, but its clinical use is limited due the potentially severe toxic effect In hypertensive patients with normal ejection fraction, the most common precursor condition of heart failure with preserved ejection fraction, the potential primary causal role of oxidative stress and inflammation in the left ventricular systolic, diastolic and atrial dysfunction, which are important determinants of the transition of hypertensive heart disease to heart failure with preserved ejection fraction was verified."	2.52	[The role of oxidative stress in amiodaron toxicity, in left ventricular dysfunction of hypertensive patients and in heart failure with preserved ejection fraction]. ( Vereckei, A, 2015)
"In patients with congestive heart failure (CHF), amiodarone was associated with a neutral survival in CHF/STAT and improvement in survival in GESICA."	2.41	Amiodarone: what have we learned from clinical trials? ( Dell'Orfano, JT; Luck, JC; Naccarelli, GV; Patel, HM; Wolbrette, DL, 2000)
"Severe ventricular arrhythmias are frequent during heart failure; they are a life-threatening condition due to the increased risk of sudden death."	1.46	[Severe ventricular arrhythmias in a patient with dilated cardiomyopathy and automated implantable defibrillator (AID)]. ( Ellenga-Mbolla, B; Gombet, TR; Ikama, SM; Kimbally-Kaky, G; Makani, J; Ondze-Kafata, LI, 2017)
"Giant cell myocarditis is a rare and highly lethal disease that is characterized by a rapidly progressive course of biventricular dysfunction."	1.37	Incessant ventricular tachycardia and cardiogenic shock: a common presentation of an uncommon diagnosis. ( Drafts, BC; Dubose, TD; Sutton, BJ; Thohan, V, 2011)
"Electrocardiography (ECG) showed ventricular tachycardia."	1.35	A case of myotonic dystrophy presenting with ventricular tachycardia and atrial fibrillation. ( Eroğlu, S; Müderrisoğlu, H; Ozbiçer, S; Ozin, B, 2009)
"The selective ablation of the recurrent ventricular tachycardia (VT) in a 75-year old patient after extensive inferior myocardial infarction (24 years ago), with low ejection fraction was performed."	1.33	[Eleven-years long follow-up in a patient after myocardial infarction, with low ejection fraction and recurrent ventricular tachycardia. The role of implantable cardioverter defibrillator and selective ablation]. ( Chojnowska, L; Derejko, P; Grzybowski, J; Iwanek, M; Kepski, R; Przybylski, A; Szumowski, Ł; Szwed, H; Urbanek, P; Walczak, F, 2006)
"On day 21, he was complicated with acute respiratory distress syndrome."	1.33	Fatal case of amiodarone-induced acute respiratory distress syndrome in a patient with severe left ventricular dysfunction due to extensive anterior acute myocardial infarction. ( Ando, H; Eto, Y; Fukumoto, Y; Ikeuchi, M; Kishi, T; Kuwata, K; Nakamura, R; Okamatsu, S; Ozawa, M; Sekiya, M; Sobashima, A; Yamada, A; Yamawaki, T, 2006)
"Cardiac mortality and sudden cardiac death rates also were higher in group 3 patients."	1.32	Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol. ( de Paola, AA; Fenelon, G; Friedman, PA; Leite, LR; Silva, GG; Simoes, A, 2003)
"Average follow up at first AF recurrence was 18."	1.31	Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters. ( Bacchi Reggiani, L; Bartolotti, M; Biffi, M; Boriani, G; Branzi, A; Zannoli, R, 2002)
" The data were analyzed by nonlinear mixed-effects modeling (NONMEM) to estimate the population pharmacokinetic parameters of amiodarone and to determine the significant demographic covariates affecting these parameters."	1.30	Population pharmacokinetics of intravenous amiodarone and comparison with two-stage pharmacokinetic analysis. ( Chiang, ST; Korth-Bradley, J; Troy, S; Vadiei, K; Zimmerman, JJ, 1997)
"In severe dilated cardiomyopathy after one year amiodarone treatment there was a significant decrease of heart rate, the new Doppler index and a significant increase of ejection fraction, ejection time and relative diastolic filling time."	1.30	[Effect of chronic amiodarone therapy on left ventricular function in dilated cardiomyopathy studied by the new Doppler-index]. ( Lengyel, M, 1998)

Research

Studies (78)

Authors

Clinical Trials (34)

Trial Overview

Trial Outcomes

Adjudicated Cardiovascular Death

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	24 (30.77)	18.2507
2000's	36 (46.15)	29.6817
2010's	17 (21.79)	24.3611
2020's	1 (1.28)	2.80

Authors	Studies
Cappellani, D	1
Papini, P	1
Di Certo, AM	1
Morganti, R	1
Urbani, C	1
Manetti, L	1
Tanda, ML	1
Cosentino, G	1
Marconcini, G	1
Materazzi, G	2
Martino, E	2
Bartalena, L	2
Bogazzi, F	2
Ikama, SM	1
Makani, J	1
Ellenga-Mbolla, B	1
Ondze-Kafata, LI	1
Gombet, TR	1
Kimbally-Kaky, G	1
Conde, D	1
Costabel, JP	1
Alves de Lima, A	1
Cadrin-Tourigny, J	2
Wyse, DG	2
Roy, D	2
Blondeau, L	1
Levesque, S	1
Talajic, M	2
Andrade, JG	1
Dubuc, M	2
Thibault, B	2
Guerra, PG	2
Macle, L	1
Rivard, L	1
Khairy, P	2
Vereckei, A	1
Bobbo, M	1
Pinamonti, B	2
Merlo, M	2
Stolfo, D	1
Iorio, A	1
Ramani, F	1
Barbati, G	2
Carriere, C	1
Massa, L	1
Poli, S	1
Scapol, S	1
Gigli, M	1
Di Lenarda, A	2
Sinagra, G	2
Nattel, S	1
Dorian, P	1
Lee, KL	1
Bourassa, MG	1
Arnold, JM	1
Buxton, AE	1
Camm, AJ	3
Connolly, SJ	2
Ducharme, A	1
Hohnloser, SH	2
Lambert, J	1
Le Heuzey, JY	1
O'Hara, G	1
Pedersen, OD	1
Rouleau, JL	1
Singh, BN	1
Stevenson, LW	1
Stevenson, WG	2
Waldo, AL	1
Køber, L	1
Torp-Pedersen, C	2
McMurray, JJ	1
Gøtzsche, O	1
Lévy, S	1
Crijns, H	1
Amlie, J	1
Carlsen, J	1
Fournier, A	1
Andelfinger, G	1
Preobrazhenskiĭ, DV	1
Lewalter, T	1
Nitschmann, S	1
Dai, SM	1
Zhang, S	1
Chen, KP	1
Hua, W	1
Wang, FZ	1
Chen, X	1
Thomas, SP	1
Eroğlu, S	1
Ozin, B	1
Ozbiçer, S	1
Müderrisoğlu, H	1
Tsuda, E	1
Matsuo, M	1
Sakaguchi, H	1
Hayashi, T	1
Hosoda, K	1
Miyazaki, A	1
Santiago, JJ	1
Dávila, CA	1
Davila, DF	1
Donis, JH	1
Villaroel, V	1
Crijns, HJ	2
van Eickels, M	1
Gaudin, C	1
Page, RL	1
Levine, TB	1
Giles, T	1
Radzik, D	1
Ghali, JK	1
Coceani, M	2
Molinaro, S	1
Scalese, M	1
Landi, P	1
Carpeggiani, C	1
L'abbate, A	1
Iervasi, G	1
Pingitore, A	1
Osaka, T	1
Yokoyama, E	1
Hasebe, H	1
Kodama, I	1
Dragos, AM	1
Pyxaras, SA	1
Pivetta, A	1
Morgera, T	1
Mestroni, L	1
Drafts, BC	1
Sutton, BJ	1
Dubose, TD	1
Thohan, V	1
Schamroth, CL	1
Tomisti, L	1
Rossi, G	1
Marchello, A	1
Moretti, M	1
De Napoli, L	1
Mariotti, R	1
Miccoli, P	1
Saklani, P	1
Skanes, A	1
Hein, W	1
Ellringmann, U	1
Vollmann, D	1
Rostock, T	1
Schott, P	1
Wilkoff, BL	1
Cook, JR	1
Epstein, AE	2
Greene, HL	1
Hallstrom, AP	2
Hsia, H	1
Kutalek, SP	1
Sharma, A	1
Emori, T	1
Ohta, K	1
Kusano, K	1
Morita, H	1
Matsubara, H	1
Sano, S	1
Ohe, T	1
Kowey, PR	1
Yan, GX	1
Winkel, E	1
Kao, W	1
Khan, IA	1
Mehta, NJ	1
Gowda, RM	1
Hauser, TH	2
Pinto, DS	2
Josephson, ME	2
Zimetbaum, P	2
Leite, LR	1
Fenelon, G	1
Simoes, A	1
Silva, GG	1
Friedman, PA	1
de Paola, AA	1
Exner, DV	1
Klein, GJ	1
Shiga, T	1
Hosaka, F	1
Wakaumi, M	1
Matsuda, N	1
Tanizaki, K	1
Kajimoto, K	1
Shoda, M	1
Hagiwara, N	1
Kasanuki, H	1
Izawa, A	1
Kinoshita, O	1
Shiba, Y	1
Takahashi, W	1
Uchikawa, S	1
Imamura, H	1
Owa, M	1
Kubo, K	1
Kanopskiĭ, SG	1
Staritskiĭ, AG	2
Bozhko, AA	2
Kanorskiĭ, SG	1
Nul, D	1
Zambrano, C	1
Diaz, A	1
Ferrante, D	1
Varini, S	1
Soifer, S	2
Grancelli, H	1
Doval, H	1
O'Sullivan, AJ	1
Lewis, M	1
Diamond, T	1
Fukumoto, Y	1
Yamada, A	1
Ando, H	1
Sobashima, A	1
Kuwata, K	1
Yamawaki, T	1
Nakamura, R	1
Eto, Y	1
Kishi, T	1
Ikeuchi, M	1
Sekiya, M	1
Ozawa, M	1
Okamatsu, S	1
Przybylski, A	1
Derejko, P	1
Iwanek, M	1
Urbanek, P	1
Kepski, R	1
Grzybowski, J	1
Chojnowska, L	1
Szumowski, Ł	1
Szwed, H	1
Walczak, F	1
Sánchez-Lázaro, IJ	1
Almenar, L	1
Martinez-Dolz, L	1
Chamorro, C	1
Moro, J	1
Agüero, J	1
Rueda, J	1
Zorio, E	1
Arnau, MA	1
Salvador, A	1
Chockalingam, A	1
Tejwani, L	1
Aggarwal, K	1
Dellsperger, KC	1
Franklyn, JA	1
Gammage, MD	1
Marçon, O	1
Brembilla-Perrot, B	1
Szabó, BM	1
Wiesfeld, AC	1
van Veldhuisen, DJ	1
Hillege, HL	1
Lie, KI	1
Garguichevich, JJ	1
Ramos, JL	1
Gambarte, A	1
Gentile, A	1
Hauad, S	1
Scapin, O	2
Sirena, J	1
Tibaldi, M	1
Toplikar, J	1
Seidl, K	1
Hauer, B	1
Schwick, N	1
Buechele, T	1
Schilling, I	1
Senges, J	1
Williams, MJ	1
Low, CJ	1
Restieaux, NJ	1
Mannino, MM	1
Mehta, D	1
Langan, NM	1
Gomes, JA	1
Ridker, PM	1
Kumar, A	1
Doval, HC	1
Nul, DR	1
Grancelli, HO	1
Varini, SD	1
Corrado, G	1
Dubner, S	1
Perrone, SV	1
Julian, DG	1
Frangin, G	1
Janse, MJ	1
Munoz, A	1
Schwartz, PJ	1
Simon, P	1
Nisam, S	1
Norris, RM	1
Pinski, SL	1
Vadiei, K	1
Troy, S	1
Korth-Bradley, J	1
Chiang, ST	1
Zimmerman, JJ	1
Campbell, TJ	1
Lengyel, M	1
Yamada, S	1
Yamaguchi, I	1
Celiker, A	1
Ceviz, N	1
Ozme, S	1
Farré, J	1
Romero, J	1
Rubio, JM	1
Ayala, R	1
Castro-Dorticós, J	1
Klein, H	2
Auricchio, A	1
Reek, S	1
Geller, C	1
Hedman, AE	1
Poloniecki, JD	1
Malik, M	1
Domanski, MJ	1
Sakseena, S	1
Brodsky, MA	1
Kim, S	1
Lancaster, S	1
Schron, E	1
Myerburg, RJ	1
Castellanos, A	1
Naccarelli, GV	1
Wolbrette, DL	1
Dell'Orfano, JT	1
Patel, HM	1
Luck, JC	1
Sweeney, MO	1
Sanders, GD	1
Hlatky, MA	1
Every, NR	1
McDonald, KM	1
Heidenreich, PA	1
Parsons, LS	1
Owens, DK	1
Moss, AJ	1
Zareba, W	1
Hall, WJ	1
Wilber, DJ	1
Cannom, DS	1
Daubert, JP	1
Higgins, SL	1
Brown, MW	1
Andrews, ML	1
Aiba, T	1
Kurita, T	1
Taguchi, A	1
Shimizu, W	1
Suyama, K	1
Aihara, N	1
Kamakura, S	1
Biffi, M	1
Boriani, G	1
Bartolotti, M	1
Bacchi Reggiani, L	1
Zannoli, R	1
Branzi, A	1
Schläpfer, J	1
Rapp, F	1
Kappenberger, L	1
Fromer, M	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Atrial Fibrillation and Congestive Heart Failure (AF-CHF)Trial[NCT00597077]	Phase 4	1,376 participants (Actual)	Interventional	2001-04-30	Completed
A Randomised Trial to Assess Catheter Ablation Versus Rate-Control in the Management of Persistent Atrial Fibrillation in Chronic Heart Failure[NCT00878384]		52 participants (Actual)	Interventional	2009-04-30	Completed
Pragmatic Randomized Clinical Trial of Early Dronedarone Versus Usual Care to Change and Improve Outcomes in Persons With First-Detected Atrial Fibrillation[NCT05130268]	Phase 4	3,000 participants (Anticipated)	Interventional	2021-10-29	Active, not recruiting
Using Time-dependent Intravenous Infusions of Amiodarone for Conversions to Sinus Rhythms in Patients With Paroxysmal Atrial Fibrillation[NCT03432663]	Phase 4	60 participants (Actual)	Interventional	2008-08-01	Completed
Antiarrhythmic Trial With Dronedarone in Moderate to Severe CHF Evaluating Morbidity Decrease[NCT00696631]	Phase 3	653 participants (Actual)	Interventional	2002-06-30	Terminated (stopped due to Terminated as the active treatment was associated with an increased hazard)
A Placebo-controlled,Double-blind,Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg Bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter (AF/AFL)[NCT00174785]	Phase 3	4,628 participants (Actual)	Interventional	2005-06-30	Completed
Cardiac Resynchronization Therapy With Synchronized RV Pacing to Improve Cardiac Function in Patients With Right Bundle Branch Block and Systolic LV Dysfunction[NCT05936294]		5 participants (Actual)	Interventional	2017-09-15	Terminated (stopped due to Low enrollment)
CRM and Fusion Beats: Effects of Progressive Fusion on Intra-left Ventricular Mechanical Function[NCT00610896]		25 participants (Actual)	Observational	2008-01-31	Completed
A Randomized, Prospective Multicenter Study to Determine the Incidence of Atrial Fibrillation and Heart Failure in Correlation to Stimulation Modes of Pacemakers[NCT00161551]	Phase 4	402 participants (Anticipated)	Interventional	2004-11-30	Recruiting
IntAct, Study on Promotion of Intrinsic Activity.[NCT00156741]	Phase 4	150 participants	Interventional	2004-04-30	Active, not recruiting
A Single Center Prospective, Pilot Study Examining the Non-invasive Evaluation of Ventricular Synchrony in Pediatric Patients[NCT00165932]		145 participants (Actual)	Observational	2004-06-30	Completed
Left Ventricular Septum Pacing in Patients by Transvenous Approach Through the Inter-ventricular Septum - Feasibility, Long-term Lead Stability and Safety[NCT01609738]		12 participants (Actual)	Observational	2012-11-30	Completed
Impact of Atrio-ventricular Optimization With His Bundle Pacing on Treatment of Atrio-ventricular Dromotropathy[NCT04544345]		17 participants (Actual)	Interventional	2019-12-23	Completed
PReventive Effect Of Left Bundle Branch Area Pacing Versus righT vEntricular paCing on All Cause deaTh, Heart Failure Progression, and Ventricular dysSYNChrony in Patients With Substantial Ventricular Pacing (PROTECT-SYNC): Multicenter Prospective Randomi[NCT05585411]		450 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Comparison of Right Ventricular Septal Pacing to Minimized Right Ventricular Septal Stimulation in Patients With Sick Sinus Syndrome[NCT01477138]		126 participants (Anticipated)	Observational	2011-07-31	Recruiting
The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study[NCT05109364]	Phase 2	15 participants (Anticipated)	Interventional	2022-09-23	Recruiting
The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease[NCT03775096]	Phase 2	15 participants (Anticipated)	Interventional	2019-04-04	Recruiting
Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients With Atrial Tachyarrhythmias[NCT03413150]		80 participants (Actual)	Observational	2007-01-31	Completed
Acute Mechanical Response to Anti-arrhythmic Drug Therapy[NCT02575534]		0 participants (Actual)	Interventional	2015-10-31	Withdrawn (stopped due to No enrollment in study.)
Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator (CALYPSO) PILOT TRIAL[NCT01576042]		27 participants (Actual)	Interventional	2012-05-31	Terminated (stopped due to Main objectives of the study were met; consensus among investigators that continuing the study would not add new information beyond that already learned.)
[NCT00000531]	Phase 3	0 participants	Interventional	1992-09-30	Completed
A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs)[NCT02026102]		15 participants (Actual)	Interventional	2014-09-30	Completed
STereotactic Ablative Radiosurgery of Recurrent Ventricular Tachycardia in Structural Heart Disease[NCT03819504]		0 participants (Actual)	Interventional	2018-08-01	Withdrawn (stopped due to Change in the design of the study)
Phase I/II Study of 4-D Navigated Non-invasive Radiosurgical Ablation of Ventricular Tachycardia[NCT03601832]		10 participants (Actual)	Interventional	2018-08-01	Completed
VOYAGE- Ventricular Tachycardia Ablation and Myocardial Scar Characterization With Magnetic Resonance[NCT04694079]	Phase 3	103 participants (Anticipated)	Interventional	2020-08-03	Recruiting
STereotactic Ablative Radiosurgery of Recurrent Ventricular Tachycardia in Structural Heart Disease[NCT04612140]		100 participants (Actual)	Interventional	2020-10-01	Completed
A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart[NCT00326690]		0 participants (Actual)	Interventional	2005-11-30	Withdrawn (stopped due to Unable to recruit and enroll patients)
Arrhythmia Prediction Trial and Risk Stratification in Heart Failure Patients - Athens.[NCT02175836]		500 participants (Anticipated)	Observational	2007-10-31	Recruiting
CMR Based Prediction of Ventricular Tachycardia Events in Healed Myocardial Infarction (DEVELOP-VT)[NCT04599439]		1,000 participants (Anticipated)	Observational [Patient Registry]	2020-08-01	Recruiting
An Intervention to Improve ICD Deactivation Conversations (WISDOM - Working to Improve discuSsions About DefibrillatOr Management)[NCT01459744]		562 participants (Actual)	Interventional	2011-09-30	Completed
Preventive VT Substrate Ablation in Patients With Chronic Post-MI Scar Showing Arrhythmogenic Characteristics[NCT04675073]	Phase 3	58 participants (Anticipated)	Interventional	2021-06-01	Recruiting
Effects of Surgical Monopolar Electrocautery and Optimal Electrosurgery Unit Return Pad Placement on Implantable Cardioverter Defibrillators Protocol[NCT01572246]		167 participants (Actual)	Observational	2012-05-31	Completed
Nursing Therapeutics Education and Heart Failure (HF): an Experimental Study[NCT02425488]		30 participants (Actual)	Interventional	2015-04-30	Terminated (stopped due to Feasability phase completed: Cost Evaluation)
Non-invasive Programmed Stimulation to Identify High-risk Patients With Implanted Cardioverter-defibrillator[NCT02373306]		150 participants (Anticipated)	Interventional	2013-11-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The considered event is cardiovascular death, as assessed by the blinded adjudication of the Steering Committee. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years

Cardiovascular Death

Intervention	participants (Number)
Dronedarone 400mg Bid	63
Placebo	90

The considered event is cardiovascular death, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years

Death From Any Cause

Intervention	participants (Number)
Dronedarone 400mg Bid	65
Placebo	94

The considered event is death from any cause. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years

First Hospitalization for Cardiovascular Reason

Intervention	participants (Number)
Dronedarone 400mg Bid	116
Placebo	139

The considered event is the first hospitalization for cardiovascular reason, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years

First Hospitalization for Cardiovascular Reason or Death From Any Cause

Intervention	participants (Number)
Dronedarone 400mg Bid	675
Placebo	859

The primary event is the first hospitalization for cardiovascular reason or death from any cause, whichever is earlier, as assessed by the investigator. The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years

Cardiovascular Hospitalizations

Intervention	participants (Number)
Dronedarone 400mg Bid	734
Placebo	917

Records participants hospitalized for VT during the study (NCT01576042)
Timeframe: Baseline, 6 months

Number of Participants Completed Month 3 Follow-Up

Intervention	participants (Number)
Catheter Ablation	5
Antiarrhythmic Medication	7

Records participants who completed Month 3 Follow-Up Visit (NCT01576042)
Timeframe: 3 months

Number of Participants Completed Month 6 Follow-Up

Intervention	participants (Number)
Catheter Ablation	11
Antiarrhythmic Medication	12

Records participants who completed Month 6 Follow-Up Visit (NCT01576042)
Timeframe: 6 Months

Number of Participants Had at Least One of the Efficacy Outcome Measurement

Intervention	participants (Number)
Catheter Ablation	7
Antiarrhythmic Medication	10

Records participants who had at least one of the efficacy outcome measurement (including death, hospitalization due to VT) (NCT01576042)
Timeframe: 6 Months

Number of Participants Received Treatment Assigned

Intervention	participants (Number)
Catheter Ablation	11
Antiarrhythmic Medication	14

Records participants who received study randomized treatment during the study (NCT01576042)
Timeframe: 6 months

Number of Participants Remained on Randomized Treatment Assignment

Intervention	participants (Number)
Catheter Ablation	11
Antiarrhythmic Medication	14

Records participants who only received study treatment as randomized during the entire study (NCT01576042)
Timeframe: 6 month

Number of Participants Switched to Other Arm

Intervention	participants (Number)
Catheter Ablation	6
Antiarrhythmic Medication	13

Records participants who received study treatment as randomized and later switched to other treatment arm during the study (NCT01576042)
Timeframe: 6 months

Time to First Recurrent ICD Therapy for VT

Intervention	participants (Number)
Catheter Ablation	5
Antiarrhythmic Medication	1

Days from the date of the first study treatment to the date of first ICD recurrent therapy for VT. (NCT01576042)
Timeframe: Baseline, 6 months

Article	Year
[The role of oxidative stress in amiodaron toxicity, in left ventricular dysfunction of hypertensive patients and in heart failure with preserved ejection fraction]. Orvosi hetilap, 2015, Nov-22, Volume: 156, Issue:47 Topics: Amiodarone; Anti-Arrhythmia Agents; Heart Failure; Humans; Hypertension; Oxidative Stress; Stroke Vo	2015
Novel anti-arrhythmic medications in the treatment of atrial fibrillation. Current cardiology reviews, 2012, Volume: 8, Issue:4 Topics: Acetanilides; Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as	2012
Pharmacologic and nonpharmacologic options to maintain sinus rhythm: guideline-based and new approaches. The American journal of cardiology, 2003, Mar-20, Volume: 91, Issue:6A Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Catheter Ablati	2003
Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. International journal of cardiology, 2003, Volume: 89, Issue:2-3 Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as To	2003
Dynamic left ventricular outflow tract obstruction in acute myocardial infarction with shock: cause, effect, and coincidence. Circulation, 2007, Jul-31, Volume: 116, Issue:5 Topics: Adrenergic beta-Antagonists; Aged; Algorithms; Amiodarone; Cardiac Catheterization; Diagnosis, Diffe	2007
[Ventricular arrhythmias after myocardial infarction: risk classification and treatment concepts]. Deutsche medizinische Wochenschrift (1946), 1995, May-05, Volume: 120, Issue:18 Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia A	1995
Drug therapy versus implantation of a cardiac defibrillator for the treatment of malignant arrhythmias in left ventricular dysfunction. American heart journal, 1996, Volume: 131, Issue:6 Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Defibrillators, Implantable; Female; Human	1996
The place of amiodarone: an overview of the four recent large controlled trials. Australian and New Zealand journal of medicine, 1997, Volume: 27, Issue:5 Topics: Amiodarone; Anti-Arrhythmia Agents; Controlled Clinical Trials as Topic; Death, Sudden, Cardiac; Hea	1997
Amiodarone and "primary" prevention of sudden death: critical review of a decade of clinical trials. The American journal of cardiology, 1999, Mar-11, Volume: 83, Issue:5B Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Death, Sudden, Cardiac; Female;	1999
New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. The American journal of cardiology, 1999, Mar-11, Volume: 83, Issue:5B Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable	1999
Amiodarone: what have we learned from clinical trials? Clinical cardiology, 2000, Volume: 23, Issue:2 Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Death, Sudden, Cardiac; Defibrillators	2000
Sudden death in heart failure associated with reduced left ventricular function: substrates, mechanisms, and evidence-based management, Part II. Pacing and clinical electrophysiology : PACE, 2001, Volume: 24, Issue:6 Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Death, Sudden; Digoxin; Evidence-Based	2001

Article	Year
Duration of Exposure to Thyrotoxicosis Increases Mortality of Compromised AIT Patients: the Role of Early Thyroidectomy. The Journal of clinical endocrinology and metabolism, 2020, 09-01, Volume: 105, Issue:9 Topics: Aged; Amiodarone; Cohort Studies; Disease Progression; Early Medical Intervention; Female; Humans; M	2020
[Severe ventricular arrhythmias in a patient with dilated cardiomyopathy and automated implantable defibrillator (AID)]. The Pan African medical journal, 2017, Volume: 27 Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Death, Sudden, Ca	2017
Recent-onset atrial fibrillation in patients with left ventricular dysfunction: amiodarone or vernakalant? The Canadian journal of cardiology, 2013, Volume: 29, Issue:10 Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Decision Making; Heart Rate; Huma	2013
Comparison of Patient Characteristics and Course of Hypertensive Hypokinetic Cardiomyopathy Versus Idiopathic Dilated Cardiomyopathy. The American journal of cardiology, 2017, Feb-01, Volume: 119, Issue:3 Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-	2017
Severe left ventricular dysfunction in infants with ventricular preexcitation. Heart rhythm, 2008, Volume: 5, Issue:9 Topics: Adrenergic alpha-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, Dilate	2008
[Therapeutic aims for atrial fibrillation in patients with heart failure]. Der Internist, 2009, Volume: 50, Issue:1 Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt	2009
Invited commentary. The Annals of thoracic surgery, 2009, Volume: 88, Issue:3 Topics: Age Factors; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atrial Fi	2009
A case of myotonic dystrophy presenting with ventricular tachycardia and atrial fibrillation. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2009, Volume: 37, Issue:5 Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Defibrillators, Implantable	2009
Combined amiodarone and low-dose carvedilol treatment for severe heart failure in childhood. Pediatrics international : official journal of the Japan Pediatric Society, 2010, Volume: 52, Issue:1 Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dos	2010
[Antiadrenergic rescue therapy with amiodarone in children with severe left ventricular dysfunction secondary to scorpion envenomation]. Arquivos brasileiros de cardiologia, 2010, Volume: 94, Issue:1 Topics: Adolescent; Adrenergic Antagonists; Amiodarone; Child; Child, Preschool; Clinical Protocols; Female;	2010
Thyroid hormone, amiodarone therapy, and prognosis in left ventricular systolic dysfunction. Journal of endocrinological investigation, 2011, Volume: 34, Issue:6 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Case-Control Studies; Female; Follow	2011
Effects of chronic amiodarone on the electrical restitution in the human ventricle with reference to its antiarrhythmic efficacy. Journal of cardiovascular electrophysiology, 2011, Volume: 22, Issue:6 Topics: Amiodarone; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart Rate; Heart Ventric	2011
Prognostic predictors in arrhythmogenic right ventricular cardiomyopathy: results from a 10-year registry. European heart journal, 2011, Volume: 32, Issue:9 Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Death, Sudden	2011
Incessant ventricular tachycardia and cardiogenic shock: a common presentation of an uncommon diagnosis. The American journal of the medical sciences, 2011, Volume: 342, Issue:6 Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Biopsy; Blood Chemical Analysis; Cardiac Catheterization;	2011
The perils of pharmacological treatment for obesity: a case of sibutramine-associated cardiomyopathy and malignant arrhythmias. Cardiovascular journal of Africa, 2012, Mar-12, Volume: 23, Issue:2 Topics: Amiodarone; Anti-Arrhythmia Agents; Appetite Depressants; Cardiomyopathy, Hypertrophic; Cyclobutanes	2012
Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction. The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:10 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Female; Heart Diseases; Humans; Male; Middle Aged; Postope	2012
[Recurrent failed ICD therapy of ventricular tachycardia]. Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2012, Volume: 107, Issue:8 Topics: Aged; Amiodarone; Anterior Wall Myocardial Infarction; Anti-Arrhythmia Agents; Atrioventricular Node	2012
Clusters of ventricular fibrillation in a patient with an implantable cardioverter difibrillator treated with amiodarone. Circulation journal : official journal of the Japanese Circulation Society, 2003, Volume: 67, Issue:2 Topics: Adult; Amiodarone; Angioplasty, Balloon, Coronary; Defibrillators, Implantable; Electrocardiography;	2003
Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol. Journal of cardiovascular electrophysiology, 2003, Volume: 14, Issue:6 Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Brazil; Chagas Cardiomyopathy; Death, Sudden, Cardiac; Dr	2003
Do we need a randomized trial of defibrillator therapy in every subset of patients with increased risk of sudden death? Journal of cardiovascular electrophysiology, 2003, Volume: 14, Issue:6 Topics: Amiodarone; Anti-Arrhythmia Agents; Chagas Cardiomyopathy; Death, Sudden, Cardiac; Defibrillators, I	2003
Percutaneous cardiopulmonary support aids resuscitation from sustained ventricular tachycardia. Circulation journal : official journal of the Japanese Circulation Society, 2003, Volume: 67, Issue:12 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Assisted Circulation; Humans; Imidazoles; Male; Resuscitat	2003
Early recurrence of arrhythmia in patients taking amiodarone or class 1C agents for treatment of atrial fibrillation or atrial flutter. The American journal of cardiology, 2004, May-01, Volume: 93, Issue:9 Topics: Age Factors; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atri	2004
[Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction]. Kardiologiia, 2004, Volume: 44, Issue:10 Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti	2004
Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry. Cardiovascular drugs and therapy, 2005, Volume: 19, Issue:2 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arg	2005
Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry. Cardiovascular drugs and therapy, 2005, Volume: 19, Issue:2 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arg	2005
Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry. Cardiovascular drugs and therapy, 2005, Volume: 19, Issue:2 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arg	2005
Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry. Cardiovascular drugs and therapy, 2005, Volume: 19, Issue:2 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arg	2005
Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. European journal of endocrinology, 2006, Volume: 154, Issue:4 Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Female; Goiter, Nodular; Graves Disease; Humans; Male	2006
Fatal case of amiodarone-induced acute respiratory distress syndrome in a patient with severe left ventricular dysfunction due to extensive anterior acute myocardial infarction. Fukuoka igaku zasshi = Hukuoka acta medica, 2006, Volume: 97, Issue:2 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Fatal Outcome; Humans; Male; Myocardial Infarction; Respir	2006
[Eleven-years long follow-up in a patient after myocardial infarction, with low ejection fraction and recurrent ventricular tachycardia. The role of implantable cardioverter defibrillator and selective ablation]. Kardiologia polska, 2006, Volume: 64, Issue:7 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Catheter Ablation; Defibrillators, Implantable; Electrophy	2006
Treatment of amiodarone-associated thyrotoxicosis. Nature clinical practice. Endocrinology & metabolism, 2007, Volume: 3, Issue:9 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Carbimazole; Hormone Replacement Therapy; Humans; Hypothyr	2007
[Bi-tachycardia and ischemic cardiopathy (following myocardial infarction)]. Archives des maladies du coeur et des vaisseaux, 2007, Volume: 100, Issue:10 Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Echocardiography; Electrophysiology; Female; Humans	2007
Use of amiodarone. JAMA, 2007, Dec-12, Volume: 298, Issue:22 Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Heart Failure; Humans; Vasodilator Age	2007
Tachycardia and cardiomyopathy. The New Zealand medical journal, 1996, Mar-08, Volume: 109, Issue:1017 Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiomegaly; Child; Chronic Disease; Electrocardiography; Femal	1996
Should survivors of myocardial infarction with low ejection fraction be routinely referred to arrhythmia specialists? JAMA, 1996, Aug-14, Volume: 276, Issue:6 Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Defibrillators, Im	1996
Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function. Southern medical journal, 1996, Volume: 89, Issue:8 Topics: Acute Disease; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Critic	1996
Do MADIT results apply only to "MADIT patients"? Multicenter Automatic Defibrillator Implantation Trial. The American journal of cardiology, 1997, Mar-20, Volume: 79, Issue:6A Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Defibrillators, Implantable; Humans; Multi	1997
[Modern therapy of tachycardiac heart arrhythmias]. Der Internist, 1995, Volume: 36, Issue:9 Suppl Mo Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fibrillation; Atrial Flutter; Humans;	1995
Amiodarone after myocardial infarction: EMIAT and CAMIAT trials. Lancet (London, England), 1997, Jun-14, Volume: 349, Issue:9067 Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Myocardial Infarction; Ventricular Dysfunction, Left	1997
Amiodarone after myocardial infarction: EMIAT and CAMIAT trials. Lancet (London, England), 1997, Jun-14, Volume: 349, Issue:9067 Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Humans; Myocardial Infarction; Ventric	1997
Population pharmacokinetics of intravenous amiodarone and comparison with two-stage pharmacokinetic analysis. Journal of clinical pharmacology, 1997, Volume: 37, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Injections, Intr	1997
[Effect of chronic amiodarone therapy on left ventricular function in dilated cardiomyopathy studied by the new Doppler-index]. Orvosi hetilap, 1998, May-10, Volume: 139, Issue:19 Topics: Adolescent; Adult; Aged; Amiodarone; Cardiomyopathy, Dilated; Dose-Response Relationship, Drug; Echo	1998
Effect of relatively low dose amiodarone therapy on left ventricular function in patients with ventricular tachyarrhythmias. Japanese circulation journal, 1998, Volume: 62, Issue:9 Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Disease Pro	1998
[Further data on amiodarone. Evidence based therapy of cardiac arrhythmias]. Der Internist, 1998, Volume: 39, Issue:11 Suppl E Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Humans; Ventricular D	1998
Effectiveness and safety of intravenous amiodarone in drug-resistant tachyarrhythmias of children. Acta paediatrica Japonica : Overseas edition, 1998, Volume: 40, Issue:6 Topics: Amiodarone; Anti-Arrhythmia Agents; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Infa	1998
Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Annals of internal medicine, 2001, Nov-20, Volume: 135, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cost-Benef	2001
Long-term efficacy of empirical chronic amiodarone therapy in patients with sustained ventricular tachyarrhythmia and structural heart disease. Circulation journal : official journal of the Japanese Circulation Society, 2002, Volume: 66, Issue:4 Topics: Amiodarone; Anti-Arrhythmia Agents; Female; Follow-Up Studies; Heart Diseases; Humans; Male; Middle	2002
Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters. Heart (British Cardiac Society), 2002, Volume: 87, Issue:5 Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Electro	2002

amiodarone and Ventricular Dysfunction, Left